236 related articles for article (PubMed ID: 19666471)
1. Heterodimerization of the sialidase NEU1 with the chaperone protective protein/cathepsin A prevents its premature oligomerization.
Bonten EJ; Campos Y; Zaitsev V; Nourse A; Waddell B; Lewis W; Taylor G; d'Azzo A
J Biol Chem; 2009 Oct; 284(41):28430-28441. PubMed ID: 19666471
[TBL] [Abstract][Full Text] [Related]
2. [Orientation of three lysosomal enzymes in the mouse inner ear and hearing loss in enzyme gene deficiency].
Guo YK; Xie DH; Yang XM
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):79-84. PubMed ID: 16562682
[TBL] [Abstract][Full Text] [Related]
3. New mutations in the PPBG gene lead to loss of PPCA protein which affects the level of the beta-galactosidase/neuraminidase complex and the EBP-receptor.
Malvagia S; Morrone A; Caciotti A; Bardelli T; d'Azzo A; Ancora G; Zammarchi E; Donati MA
Mol Genet Metab; 2004 May; 82(1):48-55. PubMed ID: 15110321
[TBL] [Abstract][Full Text] [Related]
4. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
[TBL] [Abstract][Full Text] [Related]
5. The NEU1-selective sialidase inhibitor, C9-butyl-amide-DANA, blocks sialidase activity and NEU1-mediated bioactivities in human lung in vitro and murine lung in vivo.
Hyun SW; Liu A; Liu Z; Cross AS; Verceles AC; Magesh S; Kommagalla Y; Kona C; Ando H; Luzina IG; Atamas SP; Piepenbrink KH; Sundberg EJ; Guang W; Ishida H; Lillehoj EP; Goldblum SE
Glycobiology; 2016 Aug; 26(8):834-49. PubMed ID: 27226251
[TBL] [Abstract][Full Text] [Related]
6. Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency.
Luu AR; Wong C; Agrawal V; Wise N; Handyside B; Lo MJ; Pacheco G; Felix JB; Giaramita A; d'Azzo A; Vincelette J; Bullens S; Bunting S; Christianson TM; Hague CM; LeBowitz JH; Yogalingam G
J Biol Chem; 2020 Sep; 295(39):13556-13569. PubMed ID: 32727849
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of pathogenesis in a glycosphingolipid and a glycoprotein storage disease.
d'Azzo A; Bonten E
Biochem Soc Trans; 2010 Dec; 38(6):1453-7. PubMed ID: 21118106
[TBL] [Abstract][Full Text] [Related]
8. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Bonten EJ; Yogalingam G; Hu H; Gomero E; van de Vlekkert D; d'Azzo A
Biochim Biophys Acta; 2013 Oct; 1832(10):1784-92. PubMed ID: 23770387
[TBL] [Abstract][Full Text] [Related]
9. Elastogenesis in cultured dermal fibroblasts from patients with lysosomal beta-galactosidase, protective protein/cathepsin A and neuraminidase-1 deficiencies.
Tatano Y; Takeuchi N; Kuwahara J; Sakuraba H; Takahashi T; Takada G; Itoh K
J Med Invest; 2006 Feb; 53(1-2):103-12. PubMed ID: 16538002
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1.
Seyrantepe V; Hinek A; Peng J; Fedjaev M; Ernest S; Kadota Y; Canuel M; Itoh K; Morales CR; Lavoie J; Tremblay J; Pshezhetsky AV
Circulation; 2008 Apr; 117(15):1973-81. PubMed ID: 18391110
[TBL] [Abstract][Full Text] [Related]
11. Protective protein/cathepsin A rescues N-glycosylation defects in neuraminidase-1.
Wang D; Zaitsev S; Taylor G; d'Azzo A; Bonten E
Biochim Biophys Acta; 2009 Apr; 1790(4):275-82. PubMed ID: 19714866
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal high molecular weight multienzyme complex.
Ostrowska H; Krukowska K; Kalinowska J; Orłowska M; Lengiewicz I
Cell Mol Biol Lett; 2003; 8(1):19-24. PubMed ID: 12655352
[TBL] [Abstract][Full Text] [Related]
13. Targeting macrophages with baculovirus-produced lysosomal enzymes: implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis.
Bonten EJ; Wang D; Toy JN; Mann L; Mignardot A; Yogalingam G; D'Azzo A
FASEB J; 2004 Jun; 18(9):971-3. PubMed ID: 15084520
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal multienzyme complex: pros and cons of working together.
Bonten EJ; Annunziata I; d'Azzo A
Cell Mol Life Sci; 2014 Jun; 71(11):2017-32. PubMed ID: 24337808
[TBL] [Abstract][Full Text] [Related]
15. Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis.
Caciotti A; Donati MA; Boneh A; d'Azzo A; Federico A; Parini R; Antuzzi D; Bardelli T; Nosi D; Kimonis V; Zammarchi E; Morrone A
Hum Mutat; 2005 Mar; 25(3):285-92. PubMed ID: 15714521
[TBL] [Abstract][Full Text] [Related]
16. Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A.
van der Spoel A; Bonten E; d'Azzo A
EMBO J; 1998 Mar; 17(6):1588-97. PubMed ID: 9501080
[TBL] [Abstract][Full Text] [Related]
17. Impact of beta-galactosidase mutations on the expression of the canine lysosomal multienzyme complex.
Kreutzer R; Kreutzer M; Sewell AC; Techangamsuwan S; Leeb T; Baumgärtner W
Biochim Biophys Acta; 2009 Oct; 1792(10):982-7. PubMed ID: 19607915
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy corrects the neurological deficits of mice with sialidosis.
Hwu WL; Chang K; Liu YH; Wang HC; Lee NC; Chien YH
Gene Ther; 2024 May; 31(5-6):263-272. PubMed ID: 38321198
[TBL] [Abstract][Full Text] [Related]
19. Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept.
Cadaoas J; Hu H; Boyle G; Gomero E; Mosca R; Jayashankar K; Machado M; Cullen S; Guzman B; van de Vlekkert D; Annunziata I; Vellard M; Kakkis E; Koppaka V; d'Azzo A
Mol Ther Methods Clin Dev; 2021 Mar; 20():191-203. PubMed ID: 33426146
[TBL] [Abstract][Full Text] [Related]
20. Galactosialidosis: historic aspects and overview of investigated and emerging treatment options.
Annunziata I; d'Azzo A
Expert Opin Orphan Drugs; 2017; 5(2):131-141. PubMed ID: 28603679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
